StimLabs Launches First Umbilical Cord ECM–Derived Medical Device, Expanding Access to Advanced Wound Care
Published: 06 Jan 2026
Author: Precedence Research
StimLabs, a well-known regenerative medicine innovator, has proclaimed the commercial introduction of Allacor P. The initial medical device was created using human umbilical cord-obtained extracellular matrix (ECM). This product is a significant step in the field of biological wound care, as Allacor P is currently assigned the A Code that can now be used in more reimbursement pathways and receive coverage in more sites of service in 2025. This achievement enables care providers in various care environments to implement a new ECM-based solution that is meant to tackle complicated wound healing issues with increased flexibility and clinical confidence.
Allacor P is prescribed to treat a broad spectrum of acute and chronic wounds that cannot be easily treated because of irregular geometry or damaged healing conditions. The device is composed of human umbilical cord tissue and enriched with essential ECM components, including sufficient hyaluronic acid and collagen type I, which are crucial components in tissue repair and regeneration. The fact that it comes in a particulate form contrasts with conventional sheet-based biologics. This further enables clinicians to target the product directly over wounds of different depths, shapes, and contours and complexities.
The regulatory base of the product also enhances the clinical credibility of the product. In February 2024, the U.S. Food and Drug Administration (FDA) cleared Allacor P in combination with the umbilical cord-derived hospital solution, Corplex P, manufactured by StimLabs. Since the FDA clearance, StimLabs has placed a lot of emphasis on the production of supporting scientific evidence and the gathering of real-life clinical feedback to impact the appropriate and efficacious usage. This is an evidence-based strategy that can be seen as the company's efforts to make sure that innovation is converted into a significant patient outcome.
The introduction of Allacor P also explains the long-term strategy of creating a complete range of human tissue-derived solutions based on science, regulations, and clinical experience that StimLabs follows. The company has focused on ethical sourcing, high processing standards, and adherence to the U.S. regulatory regimes. Furthermore, StimLabs does not see Allacor P as a one-off new product release, but as a platform to develop new regenerative medicine products in the future.